Objectives To determine what proportion of cases of heterozygous familial hypercholesterolaemia would be identified by cascade screening conducted by a specialist hospital clinic, and by how much this would increase the prevalence of diagnosed cases. Setting Hospital clinic serving a population of 605,900 in Oxfordshire, UK Methods A specialist nurse obtained details of living first-degree relatives from 227 adult patients with heterozygous familial hypercholesterolaemia currently or previously attending Oxford lipid clinic after excluding 79 adults without relatives living in Oxfordshire and 48 children. Index cases were asked to invite relatives resident in Oxfordshire for testing. Results A total of 227 index cases had 1075 first-degree relatives, including 442 adults and 117 children aged o18 years resident in Oxfordshire. We excluded 171 previously screened adults and 46 for other reasons. Among 225 eligible adult relatives, 28 responders (12%) planned to consult their general practitioner and 52 (23%) attended the clinic for testing. Parents of 113 children (97%) wanted them tested. The positive diagnostic rate was 29% (15/52) in adults and 32% (36/113) in children. Screening increased prevalence by 14.4%, from 0.58/1000 (95% confidence intervals [CI] 0.52-0.65) to 0.67/1000 (95% CI 0.60-0.73), representing 33.5% of predicted cases. Conclusions Cascade screening conducted by a specialist hospital clinic within its population catchment area did not substantially increase the prevalence of diagnosed familial hypercholesterolaemia. To maximize response rates, clinic staff need to approach relatives directly. Validated age, sex and country-specific diagnostic criteria should be defined, possibly with access to DNA-based tests, to help resolve diagnostic uncertainty.
INTRODUCTION
H eterozygous familial hypercholesterolaemia is the most common autosomal dominant monogenic disorder; however, most cases remain undiagnosed and therefore untreated. 1, 2 The estimated prevalence of the condition is about two per 1000, which is derived from the number of known homozygous cases based on calculations using the Hardy-Weinberg equation. 3 Most cases are caused by mutations of the low-density lipoprotein (LDL) receptor, of which more than 800 have been reported, including about 100 identified so far in patients in the UK. 4 In 3-5% of patients, the hypercholesterolaemia is caused by a single mutation in the gene for apoB, which is the ligand for the LDL receptor. 5 More recently, defects in a third gene called protein convertase subtilisin/kexin type 9 (PCSK9) causing monogenic hypercholesterolaemia have been identified in 1-2% of patients. 6 These mutations result in accumulation of LDL cholesterol in the plasma from birth 3 and in subsequent development of tendon xanthoma, xanthelasma and markedly premature atheroma. [7] [8] [9] In the heterozygous condition the cumulative risk of a fatal or non-fatal coronary event by 60 years of age, without effective treatment, is at least 50% in men and about 30% in women; 10, 11 in young adults aged less than 40 years, the relative risk of a fatal event is increased nearly 100-fold. 7 The condition is under-diagnosed after acute myocardial infarction, and in a recent case series 10% of patients aged under 60 years were reported to have familial hypercholesterolaemia, 12 although other evidence suggests about 5% of such patients to be affected. 13 Treatment with statins has improved the prognosis substantially, 8 but cost-effective primary prevention requires early diagnosis and treatment. 14 On average, one in two first-degree relatives of probands would be expected to inherit the condition. Consequently, cascade screening of first-degree relatives using either clinical 15 or DNA-based diagnostic criteria 16 is the most effective strategy for identifying undiagnosed cases. 14 However, in the absence of a coordinated national screening programme, it is unclear what proportion of cases would be identified by a specialist hospital clinic conducting local screening, and by how much this would increase the prevalence of diagnosed cases. We therefore undertook a clinic-based cascade screening programme in a resident population of 605,900 people in Oxfordshire, UK.
PATIENTS AND METHODS
A total of 354 patients currently or previously attending the Oxford lipid clinic and meeting the diagnostic criteria of the Simon Broome Familial Hyperlipidaemia Register for definite or possible familial hypercholesterolaemia were identified by January 2002, after excluding 22 cases managed exclusively in primary care. Multiple sources of ascertainment were used to identify cases consisting of a research register (the Simon Broome Register of Familial Hyperlipidaemia), the Oxford lipid clinic computerized diagnostic register and general practice records. 1 Among the 354 patients identified, there were 48 children aged less than 18 years.
Using either pre-treatment measurements or the highest measurement on treatment, definite familial hypercholesterolaemia was defined as (1) a total cholesterol concentration >7.5 mmol/L in adults (>6.7 mmol/L in children under 16 years) or an LDL cholesterol concentration >4.9 mmol/L in adults (>4.0 mmol/L in children), plus (2) tendon xanthomata in the patient or a first-or second-degree relative. A possible diagnosis of familial hypercholesterolaemia required the first definition above plus one of the following: (1) family history of myocardial infarction before age 50 years in second-degree relative or before age 60 years in first-degree relative, or (2) family history of raised total cholesterol concentration above 7.5 mmol/L in first-or second-degree relative. 1 Approval was obtained from the Central Oxford Research Ethics Committee (COREC C00.015) to contact adult firstdegree relatives via index cases, but clinic staff were not permitted direct contact. Screening was conducted over a period of 21 months by a half-time specialist nurse. A letter was either posted or given to index cases at a routine clinic appointment, which explained the purpose of the screening programme and invited them to participate. Written informed consent was obtained before recording a family pedigree of living first-degree relatives. Patients were then given a standard information letter to hand or post to firstdegree adult relatives resident in Oxfordshire inviting them to be tested. Affected parents were offered screening of their children as part of usual care and were given the choice of testing at home or at the clinic. Relatives who attended the clinic were counselled, and written informed consent was obtained, before the total cholesterol concentration was measured on a non-fasting finger-prick capillary blood sample using a Cholestech LDX analyser (Cholestech Corporation, Hayward, CA, USA) with a coefficient of variation of 4.9%. 17 Those with diagnostic or borderline results were advised to have a confirmatory fasting venous specimen taken. As there are no UK age-specific diagnostic criteria for screening that take account of the higher pre-test probability of a positive diagnosis in first-degree relatives of probands than in the general population, the results were classified by US MedPed (Make Early Diagnosis Prevent Early Death) Program criteria using age-specific total cholesterol cut-points (age o20 years 5.7 mmol/L; 20-29 years 6.2 mmol/L; 30-39 years 7.0 mmol/L; and 40 þ years 7.5 mmol/L). 18 Prevalence rates and 95% confidence intervals (CIs) were calculated using the population of Oxfordshire at the 2001 national population census as the denominator. 19 Figure 1 shows that 227 adult index cases had 1075 firstdegree relatives, of whom 442 adults (41%) and 117 children (11%) aged less than 18 years resided in Oxfordshire. We excluded 171 previously screened unaffected adults and a further 46 who were too ill or elderly and infirm. Among 225 eligible adult relatives, 28 responders (12%) planned to consult their general practitioner and 52 (23%) attended the clinic for testing. Parents of 113 children (97%) asked for their children to be tested and, with the exception of three families, all the parents asked for the tests to be done at home. The positive diagnostic rate was 29% (15/52) in adults and 32% (36/113) in children. Based on the population of Oxfordshire at the 2001 census, cascade screening increased the prevalence by 14.4% from 0.58/ 1000 (95% CI 0.52-0.65) to 0.67/1000 (95% CI 0.60-0.73), which represents a detection rate of 33.5% based on the estimated gene frequency of 2/1000.
RESULTS

DISCUSSION
Cascade screening conducted by a specialist lipid clinic did not substantially increase the prevalence of diagnosed familial hypercholesterolaemia. It showed, however, that nearly 40% of adult first-degree relatives had been screened previously in response to routine advice provided by the clinic. It confirmed the feasibility of clinic-based cascade screening, but demonstrated a poor response to approaching relatives indirectly via the index case. There were some limitations to the study. The frequency distribution for LDL cholesterol in the general population overlaps with that for patients with heterozygous familial hypercholesterolaemia, which leads to estimated falsepositive and false-negative diagnostic rates of between 8 and 18%. 20, 21 Test performance can, however, be improved by taking account of age and should be specific to particular populations. As there are no UK diagnostic criteria for screening that are age specific and take account of the higher pre-test probability of a positive diagnosis in firstdegree relatives of probands than in the general population, we had to use the US MedPed diagnostic criteria. 18 The accuracy of these criteria when applied to a different population could not be formally assessed. However, in childhood, the MedPed diagnostic criterion for total cholesterol corresponds to an LDL cholesterol level of about 4.0 mmol/L, and a level of 3.5 mmol/L has been shown to have a 98% post-test probability of predicting an LDL receptor mutation with a 4.3% false-negative rate among children of affected families in the Netherlands. 22 Use of a higher diagnostic level in our study should have ensured few false-positive diagnoses but may have increased the number of false-negative results. A molecular genetic analysis would have provided unequivocal results, but was not undertaken because it is costly and has limited sensitivity, with positive diagnostic rates ranging from 62 to 87% in case series of patients with xanthomatous familial hypercholesterolaemia 6, 22 with much lower rates in patients without tendon xanthomata. 23 The sensitivity of DNA-based testing is, however, likely to increase, and the cost is likely to fall as new automated, higher throughput methods are developed. It should also be appreciated that our study was necessarily restricted to clinic-based cascade screening, and case finding in primary care by testing patients with earlyonset coronary artery disease, and children of young coronary fatalities might be expected to identify many previously undiagnosed cases and might have increased the prevalence of diagnosed cases further.
There are a number of reasons for the small number of cases identified in this cascade screening programme. The positive diagnostic rate was lower than predicted, which was probably partly due to decreased survival of undiagnosed cases; to some inevitable clinical misclassification of patients with polygenic hypercholesterolaemia as familial probands that would have resulted in a lower than 50% prior probability of their first-degree relatives being affected, and to a much lesser extent some misattributed paternity (the median rate reported in a recent systematic review was 3.7% 24 ). Our positive diagnostic rate of 30% compared with a rate of 37.5% reported by the DNA-based national cascade screening programme in the Netherlands. 16 The response rate among adult relatives in our study to an indirect approach via index cases was only 35%, which is too low to sustain a viable cascade screening programme. However, much higher response rates can be achieved if clinic staff contact relatives directly rather than via index cases. 16 The ethics of directly approaching family members has been contested, but an examination of the ethical arguments against it shows these to be unsubstantiated, provided permission to approach relatives is obtained from the index case. 25 While a direct approach may cause a possible breach of confidentiality, if consent from the patients to discuss their condition with a relative were withheld, this would deny relatives the opportunity of risk-reducing treatment. We recently carried out a systematic literature review of different approaches to cascade testing for familial hypercholesterolaemia and found little or no evidence of adverse effects of direct contact in seven reported studies where relatives were approached with the permission of the index case. 25 We proposed several criteria which, if met, would allow an appropriate balance to be struck between maximizing the efficiency of family tracing and respecting the interests of probands and their relatives.
Experience from the national cascade screening programme in the Netherlands from 1994 onwards 16 demonstrates that 90% of relatives respond to a direct approach and, similarly, 97% of parents in Oxfordshire agreed to their children being tested. Nevertheless, even if all nonresponding adult relatives had participated, assuming an unchanged diagnostic rate, less than 40% of the predicted cases would have been identified based on the estimated gene carrier frequency of two per 1000. Higher yields require a comprehensive national cascade testing programme. This would have enabled those first-degree relatives resident in Oxfordshire of probands living elsewhere to be identified and referred for testing.
We conclude that for cascade screening to identify most individuals with familial hypercholesterolaemia, a comprehensive national screening programme would be needed. As internal European migration increases, programmes would also need to transcend national frontiers. To maximize response rates, clinic staff should be permitted to approach relatives directly. Validated age, sex and country-specific diagnostic criteria must be established, possibly with access to DNA-based tests, to help resolve diagnostic uncertainty.
